SITC (Booth 431)
WuXi AppTec provides a full spectrum of services to support immuno-oncology research, covering all major target classes and therapeutic modalities. Our world-class discovery platform includes cutting-edge capabilities in CAR T cell therapy, biomarker discovery, bispecific antibodies, tumor models, antibody-drug conjugates, and much more. We work collaboratively to rapidly advance programs from target discovery to candidate selection and into the clinic.
We are proud to present five scientific posters at this year’s SITC conference. While you’re in San Diego, join our poster presentations and visit us at Booth 431!
| Poster | Number | Date | |
| 1 | Administration of JAK and TYK2 inhibitor successfully ameliorates the severity of T cell transfer-induced colitis in mice | 446 | Saturday Nov. 4th |
| 2 | Baricitinib treatment reduces the expansion of CD8+ T cells in C3H mice with skin grafts-induced alopecia areata | 452 | Saturday Nov. 4th |
| 3 | Combined inhibition of KRAS G12C and PD1 boosts the therapeutic efficacy via conditioning of tumor microenvironment in pre-clinical humanized NSCLC mouse model | 466 | Saturday Nov. 4th |
| 4 | Preclinical platform for nucleic acid drug evaluation: siRNA and mRNA therapeutics | 59 | Friday Nov. 3rd |
| 5 | Upregulation of drug metabolism enzymes mediates ADC resistance in a HER2-positive cancer cell line | 1162 | Saturday Nov. 4th |
Resource Links
WuXi AppTec Discovery Services
Resource Type: Brochure
Tumor Cell Panel | Screening Services
Resource Type: Brochure
Cancer Pharmacology Services
Resource Type: Brochure
WuXi Oncology and Immuno-Oncology Services
Resource Type: Brochure
